Association between non-alcoholic fatty liver disease and cancer incidence rate

Journal of Hepatology

Volumn 68, Issue 1, 2018, Pages 140-146

  Kim, Gi Ae ^a   Lee, Han Chu ^a   Choe, Jaewon ^a   Kim, Min Ju ^a   Lee, Min Jung ^a   Chang, Hye Sook ^a   Bae, In Young ^a   Kim, Hong Kyu ^a   An, Jihyun ^a   Shim, Ju Hyun ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cancer; Incidence rate; Noninvasive fibrosis score

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; KOREA; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 85035112677     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.09.012     Document Type: Article

References (35)

1. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
2. European Association for the Study of the Liver European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.
3. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 19 (2013), 325–348.
4. Armstrong, M.J., Adams, L.A., Canbay, A., Syn, W.K., Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
5. Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–S64.
6. Chacko, K.R., Reinus, J., Extrahepatic complications of nonalcoholic fatty liver disease. Clin Liver Dis 20 (2016), 387–401.
7. Kim, D., Kim, W.R., Kim, H.J., Therneau, T.M., Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
8. Younossi, Z.M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
9. Wong, V.W., Wong, G.L., Tsang, S.W., Fan, T., Chu, W.C., Woo, J., et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 60 (2011), 829–836.
10. Ahn, J.S., Sinn, D.H., Min, Y.W., Hong, S.N., Kim, H.S., Jung, S.H., et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 45 (2017), 345–353.
11. Saverymuttu, S.H., Joseph, A.E., Maxwell, J.D., Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 292 (1986), 13–15.
12. Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
13. Sterling, R.K., Lissen, E., Clumeck, N., Sola, R., Correa, M.C., Montaner, J., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43 (2006), 1317–1325.
14. Seo, H.J., Oh, I.H., Yoon, S.J., A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev 13 (2012), 6163–6168.
15. Sorensen, H.T., Mellemkjaer, L., Jepsen, P., Thulstrup, A.M., Baron, J., Olsen, J.H., et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 36 (2003), 356–359.
16. Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 107 (2012), 253–261.
17. Mittal, S., El-Serag, H.B., Sada, Y.H., Kanwal, F., Duan, Z., Temple, S., et al. Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 14 (2016), 124–131 e121.
18. Noureddin, M., Rinella, M.E., Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 19 (2015), 361–379.
19. Piscaglia, F., Svegliati-Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 63 (2016), 827–838.
20. Sanna, C., Rosso, C., Marietti, M., Bugianesi, E., Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci, 17, 2016.
21. Hui, J.M., Hodge, A., Farrell, G.C., Kench, J.G., Kriketos, A., George, J., Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004), 46–54.
22. Gilbert, C.A., Slingerland, J.M., Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med 64 (2013), 45–57.
23. Campbell, P.T., Deka, A., Jacobs, E.J., Newton, C.C., Hildebrand, J.S., McCullough, M.L., et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 139 (2010), 1138–1146.
24. Yamamoto, S., Nakagawa, T., Matsushita, Y., Kusano, S., Hayashi, T., Irokawa, M., et al. Visceral fat area and markers of insulin resistance in relation to colorectal neoplasia. Diabetes Care 33 (2010), 184–189.
25. Chiu, H.M., Lin, J.T., Shun, C.T., Liang, J.T., Lee, Y.C., Huang, S.P., et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol Hepatol 5 (2007), 221–229 Quiz 141.
26. Renehan, A.G., Tyson, M., Egger, M., Heller, R.F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 (2008), 569–578.
27. Arnold, M., Pandeya, N., Byrnes, G., Renehan, A.G., Stevens, G.A., Ezzati, M., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 16 (2015), 36–46.
28. Lohmann, A.E., Goodwin, P.J., Chlebowski, R.T., Pan, K., Stambolic, V., Dowling, R.J., Association of obesity-related metabolic disruptions with cancer risk and outcome. J Clin Oncol 34 (2016), 4249–4255.
29. Rosato, V., Bosetti, C., Talamini, R., Levi, F., Montella, M., Giacosa, A., et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 22 (2011), 2687–2692.
30. Agnoli, C., Berrino, F., Abagnato, C.A., Muti, P., Panico, S., Crosignani, P., et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 20 (2010), 41–48.
31. Lawlor, D.A., Smith, G.D., Ebrahim, S., Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 15 (2004), 267–275.
32. Starley, B.Q., Calcagno, C.J., Harrison, S.A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51 (2010), 1820–1832.
33. Park, S., Oh, C.M., Cho, H., Lee, J.Y., Jung, K.W., Jun, J.K., et al. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ, 355, 2016, i5745.
34. Dasarathy, S., Dasarathy, J., Khiyami, A., Joseph, R., Lopez, R., McCullough, A.J., Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 51 (2009), 1061–1067.
35. Choi, S.Y., Kim, D., Kim, H.J., Kang, J.H., Chung, S.J., Park, M.J., et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 104 (2009), 1953–1960.